18.11.2020 16:14:19
|
Stock Alert: Chiasma Up 8% On Positive Results From Acromegaly Treatment Trial
(RTTNews) - Shares of Chiasma, Inc. (CHMA) gained over 8% on Wednesday morning after reporting positive results from a late-stage trial of treatment for Acromegaly.
CHMA is currently trading at $4.37, up $0.33 or 8.17%, on the Nasdaq.
Chiasma, a biopharmaceutical company developing oral therapies for rare diseases, announced positive top-line data from its global Phase 3 non-inferiority clinical trial comparing Mycapssa to long-acting injectable somatostatin analogs in patients with acromegaly.
The study met its primary non-inferiority endpoint. 91% of patients on Mycapssa maintained insulin-like growth factor 1 response compared to compared to 100% on injectable SSAs.
The trial was designed to support a planned marketing authorization application for Mycapssa in the European Union.
Mycapssa is currently approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Chiasma Incmehr Nachrichten
Keine Nachrichten verfügbar. |